AMAG Pharmaceuticals — Q3 2019 Earnings Presentation
24 slides from AMAG Pharmaceuticals's earnings presentation, Nov 1, 2019
Slide 1: AMAG Pharmaceuticals Third Quarter 2019 Financial Results
AMAG Pharmaceuticals Third Quarter 2019 Financial Results November 1, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG
Slide 3: Cautionary Disclosure Regarding AMAG's Long-term Outlook
Cautionary Disclosure Regarding AMAG’s Long-term Outlook AMAG has made forward looking estimates of its long-term outlook, including that it will be adjusted EBITDA neutral by 2020. AMAG’s growth trajectory and expectations for adjusted EBITDA on a multi-year timeframe are based on a strategy of max
Slide 4: Agenda
Agenda 1 Q3-2019 Highlights 2 Makena FDA Advisory Committee Meeting Update 3 Vyleesi Launch Update 4 Q3 Financial Results and Guidance 5 Development Pipeline Update 6 Closing Remarks/Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 4
Slide 5: Strong Key Commercial Products' Performance
Strong Key Commercial Products’ Performance Subcutaneous Auto-injector Record Revenues & Market Share1 Quarterly Market Share2 TRx/NRx Average Market Share3 5.0% Revenues 4.5% % 63% 63% YoY: up nearly 20% 54 4.0% TRx QoQ: up more than 5% 3.5% 3.0% NRx Market share 2.5% 2.0% Q1-2019 Q2-2019 Q3-2019 1
Slide 6: Makena FDA Advisory Committee Meeting Update
Makena FDA Advisory Committee Meeting Update 6
Slide 7: Makena PROLONG Update
Makena PROLONG Update PROLONG Study Results Published (October 25) • The American Journal of Perinatology • Primary author Dr. Sean Blackwell puts results in perspective in discussion section Professional Societies Recently Updated Guidelines (October 25) • American College of Obstetricians and Gyne
Slide 8: Vyleesi National Launch – September 2019
Vyleesi National Launch – September 2019 8
Slide 9: Vyleesi Launched Nationally September 2019
Vyleesi Launched Nationally September 2019 First FDA-approved as-needed treatment option for premenopausal women1 Early experience program built demand and enhanced market knowledge ahead of launch Accelerating Approximately 125 sales professionals Engagement now targeting 15,000 HCPs Social and dig
Slide 10: Early Feedback
Early Feedback I have had 4 different providers requesting me to come by and detail Vyleesi. Those requests came from no access offices. Vyleesi sales rep WOMEN’S HEALTH: VYLEESI © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 10
Slide 11: Encouraging Early Launch Metrics
Encouraging Early Launch Metrics Early metrics through one month post launch 12.6M 120k+ 1,300+ 1 women 40.7M symptom prescribers have been impressions checkers 3,000+ reached completed prescriptions1 What you can expect post first full quarter when we report 4Q19 Early Digital & formulary Number of
Slide 12: Financial Overview
Financial Overview 12
Slide 13: Sequential Quarter Revenue Summary
Sequential Quarter Revenue Summary • Makena SC auto-injector: ($M) Q3-2019 Q2-2019 – Revenue stable at ~$40M per quarter and in-line with company expectations Makena subcutaneous (SC) $41.3 $41.0 auto-injector Makena intramuscular (IM) – (7.0) (10.0) branded and generic Total Makena $34.3 $31.0 Fera
Slide 14: Year-over-Year Quarterly Revenue Summary
Year-over-Year Quarterly Revenue Summary Third quarter 2019 financial results ($M) Q3-2019 Q3-2018 • Makena IM year-over-year decrease related to: Makena subcutaneous (SC) $41.3 $39.2 ▪ Generic entrants in July 2018 auto-injector ▪ Third-party manufacturing challenges Makena intramuscular (IM) – (7.
Slide 15: Operating Expense and Income/Loss Summary
Operating Expense and Income/Loss Summary Third quarter 2019 financial results Three Months Ended September 30, • Decline in CoPS primarily related to: – ($M) 2019 2018 Decrease in amortization expense associated with Makena IM intangible asset Amortization of intangible assets $4.2 $30.9 – Direct C
Slide 16: 2019 Financial Guidance
2019 Financial Guidance 1 Updated 2019 Guidance (November) Previous 2019 Guidance (August) ($M) Low Mid High Low Mid High Total revenue $320 $325 $330 $325 $340 $355 GAAP operating loss ($278) ($273) ($268) ($286) ($281) ($276) Non-GAAP adjusted EBITDA ($75) ($70) ($65) ($85) ($80) ($75) 1 See slide
Slide 17: Development Pipeline Update
Development Pipeline Update 17
Slide 18: Development Pipeline is Progressing
Development Pipeline is Progressing Commercial products help fund development programs Regulatory Approved/ Phase 1 Phase 2 Phase 3 Review Marketed Treatment of iron deficiency anemia Anticoagulant reversal agent Ciraparantag (potential for orphan drug designation) HEMATOLOGY Treatment to reduce rec
Slide 19: Focus: Looking Ahead
Focus: Looking Ahead Makena Continue enrollment and additional SC Auto- Maintain strong market share AMAG-423 site initiations, including EU injector FDA AdComm follow up IDE submission (Perosphere Technologies) Vyleesi Continue to drive successful launch Ciraparantag Complete healthy volunteer stud
Slide 20: AMAG Pharmaceuticals Third Quarter 2019 Financial Results Q&A
AMAG Pharmaceuticals Third Quarter 2019 Financial Results Q&A © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 20
Slide 21: Appendix
Appendix 21
Slide 22: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results ($M) Q3-2019 Q3-2018 9-Mos. 2019 9-Mos. 2018 GAAP operating income ($18.0) ($19.3) ($251.6) ($28.2) Depreciation and intangible asset amortization 4.8 31.4 13.9 146.0 Non-cash inventory step-up adjustments -- 0.4 -- 3.6 Stock-based compensation 5.
Slide 23: Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance
Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance 2019 Financial Guidance ($M) Revised Guidance Previous Guidance Operating loss ($278) – ($268) ($286) – ($276) Depreciation & intangible asset amortization 20 18 Stock-based compensation 19 19 Acquired IPR&D 75 75 Restructuring 7 7 Asset imp
Slide 24: AMAG Pharmaceuticals Third Quarter 2019 Financial Results
AMAG Pharmaceuticals Third Quarter 2019 Financial Results November 1, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 24